In our study, we initially created engineered exosomes that transported CRISPR/Cas9 plasmid DNA for in vivo targeting of carcinogenic Ythdf1. This presents a safe approach to suppressing tumor growth by restoring tumor immune surveillance. This evidence concerns the gene YTHDF1 and neoplasm.